Advertising a drug’s name and a use that is off-label is “a double whammy,” said Patrick Massad, commissioner of the Pharmaceutical Advertising Advisory Board (PAAB), an organization that is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results